Inamura Kentaro
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan.
Cancers (Basel). 2017 May 9;9(5):49. doi: 10.3390/cancers9050049.
Lung cancer is the leading cause of deaths resulting from cancer owing to late diagnosis and limited treatment intervention. MicroRNAs are short, non-coding RNA molecules that regulate gene expression post-transcriptionally by translational repression or target messenger RNA degradation. Accumulating evidence suggests various roles for microRNAs, including development and progression of lung cancers. Because microRNAs are degraded to a much lesser extent in formalin-fixed paraffin-embedded specimens and are present not only in tumor tissues but also in body fluids, there is an increased potential in microRNA analyses for cancer research. In this review, recent studies of microRNA are introduced and briefly summarized, with a focus on the association of microRNAs with histological subtypes, genetic driver alterations, therapeutically-targeted molecules, and carcinogens. The reported circulating microRNA signature for the early detection of lung cancer and the implications of microRNAs as the modulators of tumor immune response are also introduced.
肺癌是癌症致死的主要原因,这归因于诊断延迟和治疗干预有限。微小RNA是短的非编码RNA分子,通过翻译抑制或靶向信使RNA降解在转录后调节基因表达。越来越多的证据表明微小RNA具有多种作用,包括在肺癌的发生和发展过程中。由于微小RNA在福尔马林固定石蜡包埋标本中的降解程度要小得多,并且不仅存在于肿瘤组织中,还存在于体液中,因此微小RNA分析在癌症研究中的潜力有所增加。在这篇综述中,我们介绍并简要总结了微小RNA的最新研究,重点关注微小RNA与组织学亚型、基因驱动改变、治疗靶点分子和致癌物之间的关联。还介绍了已报道的用于肺癌早期检测的循环微小RNA特征以及微小RNA作为肿瘤免疫反应调节剂的意义。